Wall Street analyst estimates for Allogene Therapeutics, Inc. (ALLO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.13 | ||
| 2026-08-12 | $-0.13 | $-0.17 | +24.1% |
| 2026-05-13 | $-0.18 | $-0.19 | +5.3% |
| 2026-03-12 | $-0.17 | $-0.25 | +32.0% |
| 2025-11-06 | $-0.19 | $-0.23 | +17.4% |
| 2025-08-13 | $-0.23 | $-0.28 | +17.9% |
| 2025-05-13 | $-0.28 | $-0.28 | +0.0% |
| 2025-03-13 | $-0.28 | $-0.34 | +17.6% |
Valuation Ratios
| Price / Book | 1.14 |
| EV / EBITDA | -4.19 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | $114.1M | $156000 | $95000 | $22000 | 0 |
| Cost of Revenue | 0 | 0 | $5.0M | $11.5M | 0 | $14.3M | 0 | 0 | $12.4M |
| Gross Profit | 0 | -$1.5M | -$5.0M | -$11.5M | $114.1M | -$14.1M | $95000 | $22000 | -$12.4M |
| Research & Development | 0 | $151.9M | $144.5M | $193.0M | $220.2M | $256.4M | $242.9M | $192.3M | $150.2M |
| Selling, General & Admin | $2000 | $41.0M | $57.5M | $65.3M | $74.1M | $79.3M | $71.7M | $65.2M | $56.8M |
| Operating Expenses | $2000 | $192.8M | $202.0M | $246.7M | $294.3M | $321.4M | $327.8M | $273.2M | $194.6M |
| Operating Income | -$2000 | -$192.8M | -$202.0M | -$258.2M | -$180.2M | -$335.5M | -$327.7M | -$273.2M | -$206.9M |
| EBITDA | $22000 | -$206.8M | -$179.9M | -$238.7M | -$171.6M | -$326.1M | -$313.1M | -$243.3M | -$177.5M |
| Interest Expense | 0 | $3.4M | 0 | 0 | 0 | 0 | 0 | $181000 | $1.1M |
| Pre-tax Income | -$24000 | -$211.6M | -$184.9M | -$250.2M | -$182.1M | -$340.4M | -$327.3M | -$257.1M | -$190.9M |
| Income Tax | -$24000 | -$117000 | -$331000 | 0 | 0 | 0 | 0 | $443000 | 0 |
| Net Income | -$2000 | -$211.5M | -$184.6M | -$250.2M | -$182.1M | -$340.4M | -$327.3M | -$257.6M | -$190.9M |
| EPS | $-0.00 | $-2.36 | $-1.83 | $-2.08 | $-1.34 | $-2.38 | $-2.09 | $-1.32 | $-0.87 |
| EPS (Diluted) | $-0.00 | $-2.36 | $-1.83 | $-2.08 | $-1.34 | $-2.38 | $-2.09 | $-1.32 | $-0.87 |
| Shares Outstanding (Diluted) | $44.0M | $89.7M | $101.1M | $120.4M | $135.8M | $143.1M | $156.9M | $194.8M | $220.6M |
Price
| Price | $1.69 |
| Market Cap | $583M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACHV · AVIR · CABA · CRBU · EDIT · HUMA · IMMP
Explore sector: Healthcare · Biotechnology
More sections of ALLO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks